Alaska Medicaid Pharmacy and Therapeutics Committee Meeting

April 16, 2021

Frontier Building, 3601 C Street; Room 880/890

Please note, as a result of COVID-19 this meeting will be available via teleconference only.

Agenda

Public Call in: 1.800.315.6338. Access code 24251#

1. Call to Order – Chair

8:00 am 8:05 am

2. Roll Call

3. Public Comment

The Department's methods for class review are to better utilize the time of the P&T Committee. Classes shown in **Red** are *new classes/new drugs* and **Blue** are classes where **new information exists and industry testimony will be taken. Classes shown in **Green** are classes with no significant changes have been noted and no industry testimony will be taken.

**New information includes: new indications or drugs, new warnings, or new head to head clinical evidence.

AK Treatment Class	Drug Class	Status
Single Class Review	Hereditary Angioedema	RED**
	Hemophilia	RED**
Cardiovascular	ACE Inhibitor & Renin Inhibitors	BLUE**
	Angiotensin Receptor Blockers (ARB)	GREEN
	Angiotensin Modulator/CCB Combinations	GREEN
	Antianginal and Anti-ischemic agents	GREEN
	Anticoagulants	BLUE**
	Beta-Blockers	GREEN
	Calcium Channel Blockers	BLUE**
	Erythropoiesis Stimulating agents	BLUE**
	Lipotropics, other	RED**
	PCSK-9 Inhibitors	GREEN
	Platelet Aggregation Inhibitors	BLUE**
	Pulmonary Arterial Hypertension	BLUE**
Anti-Infective	Antifungals, oral	GREEN
	Antifungals, topical	BLUE**
	Antivirals, influenza	BLUE**
	Fluoroquinolones, oral	GREEN
	Hepatitis B agents	GREEN
	Hepatitis C agents	BLUE**
	Otic Antibiotics	GREEN
Genitourinary	Benign Prostatic Hyperplasia (BPH) agents	GREEN
	Bladder Relaxant Preparations	RED**
	Vaginal Antibiotics	BLUE**

4. Class review, discussion & vote.

- 5. Break as needed 15 minutes
- 6. Review minutes from January 2021 meeting
- 7. Comments from Committee Members or Chair
- 8. Adjourn

Next Meeting Date: September 17, 2021